Arrowhead director files Form 3 with no holdings
Arrowhead Pharmaceuticals director Matthew Gregory Cohen has filed an initial Form 3 indicating no current ownership of the company’s Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Arrowhead Pharmaceuticals director Matthew Gregory Cohen has filed an initial Form 3 indicating no current ownership of the company’s Common Stock. The filing lists a holding entry in Common Stock with total shares following the report shown as 0. This is a baseline disclosure of his position as a newly reported insider, rather than a buy or sell transaction.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Key Figures
Key Terms
Form 3 regulatory
Common Stock financial
reporting person regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Matthew Gregory Cohen’s Form 3 filing for ARWR show?
Did Matthew Gregory Cohen buy or sell Arrowhead Pharmaceuticals (ARWR) stock in this Form 3?
What role does Matthew Gregory Cohen have at Arrowhead Pharmaceuticals (ARWR)?
Does this ARWR Form 3 include any derivative securities for Matthew Gregory Cohen?
AI-generated analysis. How Rhea-AI works. Not financial advice.